Indoco Remedies

Consolidated EBITDA margin expands from (0.2%) in Q4 2024-25 to 10.9% in Q4 FY26, reflecting strong pricing and cost control

Consolidated finance costs spike from ₹180 Cr in Q4 2024-25 to ₹459 Cr in Q4 FY26, signaling heavy debt servicing pressure

Formulation Business revenue grows from ₹3,171 Cr in Q4 2024-25 to ₹4,147 Cr in Q4 FY26, confirming steady product demand

Domestic formulation revenue falls from a peak of ₹2,554 Cr in Q2 FY26 to ₹1,999 Cr in Q4 FY26, indicating local market softening

International formulation sales surge from ₹1,104 Cr in Q4 2024-25 to ₹2,147 Cr in Q4 FY26, highlighting a robust export recovery

API revenue eases from ₹431 Cr in Q2 FY26 to ₹315 Cr in Q4 FY26, showing volatile raw material demand

Allied Services revenue climbs from ₹1 Cr in Q1 FY26 to ₹89 Cr in Q4 FY26, indicating recovering traction in support operations

FII holding drops from 1.24% in Q4 2024-25 to 0.94% in Q4 FY26, reflecting sustained foreign investor exit

Consolidated operational revenue rises from ₹3,839 Cr in Q4 2024-25 to ₹4,559 Cr in Q4 FY26, reflecting resilient overall demand

Consolidated market cap contracts from ₹29,146 Cr in Q1 FY26 to ₹15,216 Cr in Q4 FY26, confirming sharp valuation compression